Previous 10 | Next 10 |
Akero Therapeutics to Participate in Upcoming Virtual Healthcare Conferences in March PR Newswire SAN FRANCISCO , Feb. 23, 2021 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformat...
Hepion's leading candidate CRV431 may have the best anti-fibrotic effect among the numerous NASH candidates. CRV431's analogs have been widely studied in various clinical trials, and were proven to be well-tolerated. Hepion's management has extensive experience with cyclophilin in...
Gainers: [[RDHL]] +25.6%. [[GOGO]] +18.6%. [[BBBY]] +17.3%. [[RYTM]] +14.6%. [[AKRO]] +13.6%.Losers: [[OPCH]] -16.7%. [[GRTX]] -16.6%. [[TTOO]] -15.3%. [[WMG]] -7.7%. [[FFIV]] -7.5%. For further details see: BBBY, RDHL, TTOO and OPCH among after-hours movers
Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today announced that management will present virtually at the 39 th An...
Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today announced that management will participate in a fireside chat at Eve...
Data to be presented at the Presidential Plenary Talk at The Liver Meeting® 100% of patients in 50mg group demonstrated more than 50% relative reduction in liver fat 50% of patients with F2/F3 fibrosis at baseline achieved two stage improvement in fibrosis score ...
Akero Therapeutics (AKRO): Q3 GAAP EPS of -$0.63 beats by $0.03.Cash, cash equivalents and short-term marketable securities of $291.9M.Press Release For further details see: Akero Therapeutics EPS beats by $0.03
Akero Therapeutics Reports Third Quarter 2020 Financial Results PR Newswire SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-a...
Akero Therapeutics To Present At Upcoming Conferences In November PR Newswire SOUTH SAN FRANCISCO, Calif., Oct. 21, 2020 SOUTH SAN FRANCISCO, Calif., Oct. 21, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnol...
The European Medicines Agency ((EMA)) has granted Priority Medicines ((PRIME)) designation to Akero Therapeutics' (AKRO) efruxifermin ((EFX)), an investigational FGF21 analog for the treatment of non-alcoholic steatohepatitis ((NASH)).PRIME, akin to Breakthrough Therapy status in the U.S., pr...
News, Short Squeeze, Breakout and More Instantly...
Akero Therapeutics Inc. Company Name:
AKRO Stock Symbol:
NASDAQ Market:
Akero Therapeutics Inc. Website:
2024-07-09 15:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-12 10:00:04 ET Edward Nash from Canaccord Genuity issued a price target of $56.00 for AKRO on 2024-06-12 07:44:00. The adjusted price target was set to $56.00. At the time of the announcement, AKRO was trading at $23.43. The overall price target consensus is at $...
SOUTH SAN FRANCISCO, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced initiation of the ...